32 Results for "

FUT8

" in MedChemExpress (MCE) Product Catalog:
Products (32)

32 Results for "FUT8" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-155747
CAS No.: 2768426-49-7
Purity:  99.41%
Target:  

Autophagy Akt mTOR

Research Areas:  

Cancer

FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-E70157
Synonyms: EC:2.4.1.68; FUT8; α1-6FucT
Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans .
loading...
    loading...
Cat. No.: HY-P99113A

Target:  

CD19

Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
loading...
    loading...
Cat. No.: HY-P99010A

Research Areas:  

Cancer

Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
loading...
    loading...
Cat. No.: HY-P99653A
Synonyms: VAY-736 (FUT8-KO)

Research Areas:  

Inflammation/Immunology Cancer

Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .
loading...
    loading...
Cat. No.: HY-P99406A

Target:  

EGFR

Research Areas:  

Cancer

Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-P9977A

Target:  

EGFR

Research Areas:  

Cancer

Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
loading...
    loading...
Cat. No.: HY-P9980A

Research Areas:  

Cancer

Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
loading...
    loading...
Cat. No.: HY-RS05159
Research Areas:  

Others

FUT8 Human Pre-designed siRNA Set A contains three designed siRNAs for FUT8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P99295A
Synonyms: RG 7160 (FUT8-KO); RO 5083945 (FUT8-KO); Anti-EGFR Recombinant Antibody (FUT8-KO)

Target:  

EGFR

Research Areas:  

Cancer

Imgatuzumab (FUT8-KO) is a humanized monoclonal antibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.
loading...
    loading...
Cat. No.: HY-170541
CAS No.: 3073704-71-6
FUT8-IN-1 (Compound 37) is an inhibitor for α-1,6-fucosyltransferase (FUT8) with an KD of 49 nM and an IC50 of ca. 50 µM. FUT8-IN-1 generates a highly active naphthoquinone imine intermediate in the presence of FUT8, and inhibits the enzymatic activity of FUT8 .
loading...
    loading...
Cat. No.: HY-RS17190
Research Areas:  

Others

Fut8 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fut8 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS23641
Research Areas:  

Others

Fut8 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fut8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P9991A

Target:  

Gap Junction Protein

Research Areas:  

Cancer

Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
loading...
    loading...
Cat. No.: HY-P99226A
Daxdilimab (FUT8-KO) is an anti-ILT7 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.
loading...
    loading...
Cat. No.: HY-P990755A

Target:  

EGFR

Research Areas:  

Cancer

Pamvatamig (FUT8-KO) is an anti-EGFR/MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody.
loading...
    loading...
Cat. No.: HY-P990902A
CAS No.: 2733581-82-1
Synonyms: BMS-986012 (FUT8-KO)

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Atigotatug (FUT8-KO) is an anti-fuc-GM1 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out, and fucose deficiency enhances the ADCC effect of the antibody. Atigotatug (HY-P990902) is a Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P990026A
Ulviprubart (FUT8-KO) is a humanized anti-KLRG1 monoclonal antibody lacking fucosyltransferase 8 (FUT8). Ulviprubart (FUT8-KO) can be used for the research of diseases such as inclusion body myositis (IBM) .
loading...
    loading...
Cat. No.: HY-P991135A
Synonyms: RO-7502175 (FUT8-KO); RG-6411 (FUT8-KO)

Target:  

CCR

Research Areas:  

Cancer

Enzelkitug (RO-7502175; RG-6411) (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. Enzelkitug (FUT8-KO) can be used for the research of various solid tumors and hematological malignancies .
loading...
    loading...
Cat. No.: HY-P991892A

Research Areas:  

Cancer

IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
loading...
    loading...